Emerald Advisers Inc. PA cut its position in shares of Intrexon Corporation (NYSE:XON) by 29.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,281 shares of the biotechnology company’s stock after selling 11,336 shares during the period. Emerald Advisers Inc. PA’s holdings in Intrexon Corporation were worth $657,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of XON. Norges Bank bought a new stake in Intrexon Corporation during the fourth quarter worth $17,300,000. CWM LLC increased its stake in Intrexon Corporation by 9,455.4% in the first quarter. CWM LLC now owns 35,546 shares of the biotechnology company’s stock worth $705,000 after buying an additional 35,174 shares during the last quarter. Private Advisor Group LLC increased its stake in Intrexon Corporation by 18.6% in the first quarter. Private Advisor Group LLC now owns 35,502 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 5,556 shares in the last quarter. Capital Fund Management S.A. increased its stake in Intrexon Corporation by 40.9% in the first quarter. Capital Fund Management S.A. now owns 127,798 shares of the biotechnology company’s stock valued at $2,533,000 after buying an additional 37,098 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Intrexon Corporation by 60.0% in the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after buying an additional 54,179 shares in the last quarter. Institutional investors own 84.52% of the company’s stock.
Intrexon Corporation (XON) traded down 1.82% during midday trading on Friday, reaching $17.30. 1,084,875 shares of the company traded hands. The stock’s 50 day moving average is $21.96 and its 200 day moving average is $21.83. The company’s market capitalization is $2.08 billion. Intrexon Corporation has a one year low of $17.05 and a one year high of $32.90.
Intrexon Corporation (NYSE:XON) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. The firm had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.42) earnings per share. On average, equities analysts anticipate that Intrexon Corporation will post ($0.87) earnings per share for the current year.
WARNING: “Emerald Advisers Inc. PA Has $657,000 Position in Intrexon Corporation (XON)” was originally published by BNB Daily and is the property of of BNB Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/emerald-advisers-inc-pa-lowers-position-in-intrexon-corporation-xon-updated-updated.html.
XON has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Tuesday, May 2nd. Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the stock a “buy” rating in a research report on Monday, August 7th. Finally, BidaskClub upgraded shares of Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $37.60.
In other Intrexon Corporation news, CEO Randal J. Kirk purchased 132,625 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average price of $18.85 per share, with a total value of $2,499,981.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dean J. Mitchell acquired 5,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was purchased at an average price of $18.33 per share, with a total value of $91,650.00. Following the acquisition, the director now owns 18,103 shares of the company’s stock, valued at approximately $331,827.99. The disclosure for this purchase can be found here. In the last three months, insiders have bought 141,719 shares of company stock valued at $2,669,554. Insiders own 55.10% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.